Company
Twist Bioscience
Our DNA-based tools are enabling researchers across a variety of scientific disciplines to achieve groundbreaking discoveries.
- Status
- IPOas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
- Customers
- Researchers
- Legal name
- Twist Bioscience Corporation
- twistbioscience.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Twist Bioscience developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high-throughput silicon platform that allows us to miniaturize the chemistry necessary for DNA synthesis.
Funding snapshot
- Total raised
- $261MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $50M2018-03-19
Funding rounds
- Round, 2018
- $50M2018-03-19, SEC form D sold, 1 investor
- Round, 2017
- $74.9M2017-03-09, SEC form D sold, 63 investors
- Round, 2016
- $2.6M2016-04-05, SEC form D sold, 46 investors
- Round, 2016
- $61M2016-01-08, SEC form D sold, 35 investors
- Round, 2015
- $37M2015-05-29, SEC form D sold, 28 investors
- Round, 2014
- $26M2014-05-13, SEC form D sold, 24 investors
- Round, 2013
- $9.1M2013-07-01, SEC form D sold, 16 investors
About the company
- Status notes
- Provides synthetic DNA for health and sustainability (NASDAQ:TWST)
Loading relationship preview